title: Premature plasma progesterone and androgen elevation are not prevented by adrenal suppression in in vitro fertilization.
abstract: OBJECTIVE
  To investigate the effects of adrenal suppression with dexamethasone (DEX) on P and androgen profiles during controlled ovarian hyperstimulation (COH) for IVF-ET.
  
  
  METHODS
  Prospective controlled trial.
  
  
  METHODS
  In vitro fertilization program, Clamart, France.
  
  
  METHODS
  One hundred twenty IVF-ET candidates aged 25 to 39 years undergoing 120 COH cycles.
  
  
  METHODS
  Group A: 60 women received a time-release GnRH agonist (GnRH-a) on cycle day 2. After pituitary desensitization was confirmed, 1 mg/d DEX was administered daily until hCG. Ovarian stimulation with hMG was started on the 7th day of DEX. Group B: 60 other women received an identical treatment except DEX was omitted.
  
  
  METHODS
  Plasma E2, P, androstenedione (A), and T were measured 18 days after GnRH-a, on the 7th day of DEX in group A, and on the day of hCG.
  
  
  RESULTS
  Peak plasma E2 levels were similar in groups A and B. After GnRH-a, P and androgen levels were low in both groups. In group A, an additional decrease in these hormones was observed after 7 days of DEX. During COH, we observed similar absolute increases of P, A, and T in groups A (+0.52, +1.56, and +0.12 ng/mL, respectively) and B (+0.55, +1.66, and +0.17 ng/mL, respectively).
  
  
  CONCLUSIONS
  As expected, DEX lowered additionally P, A, and T levels from values achieved after GnRH-a alone, reflecting the adrenal contribution to the circulating levels of these hormones at baseline. Yet, the net increases in P, A, and T seen in COH were unaltered by DEX treatment, indicating that this phenomenon results solely from an effect of exogenous gonadotropins on the ovary.
authors.affiliation: Department of Obstetrics and Gynecology, Hôpital Antoine Béclère, Clamart, France.
authors.forename: R
authors.initials: R
authors.lastname: Fanchin
authors.forename: C
authors.initials: C
authors.lastname: Righini
authors.forename: F
authors.initials: F
authors.lastname: Olivennes
authors.forename: J
authors.initials: J
authors.lastname: Taieb
authors.forename: D
authors.initials: D
authors.lastname: de Ziegler
authors.forename: R
authors.initials: R
authors.lastname: Frydman
mesh_terms: D000311:Adrenal Glands / Q000187:drug effects*; D000328:Adult; D000728:Androgens / Q000097:blood*; D003907:Dexamethasone / Q000494:pharmacology*; D005260:Female; D005307:Fertilization in Vitro; D006801:Humans; D008596:Menotropins / Q000494:pharmacology; D010053:Ovary / Q000187:drug effects; D011374:Progesterone / Q000097:blood*; D011446:Prospective Studies
chemical_list: D000728:Androgens; D011374:Progesterone; D008596:Menotropins; D003907:Dexamethasone